NOVN.SW
$121.44
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart f...
Recent News
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State
Julius Baer’s $30 Million Pay Package Shows the Price of a Banking Reset
The Swiss private bank paid its new boss more than UBS chief Sergio Ermotti, highlighting how costly it can be to rebuild credibility after a major scandal
FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents
Novartis wins FDA nod to expand Cosentyx use to teens with hidradenitis suppurativa, making it the only IL-17A inhibitor for this group.
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
Gilead plans a $7.8B Arcellx acquisition as cell therapy sales decline, seeking full control of anito-cel to strengthen its oncology pipeline.
Assessing Novartis (SWX:NOVN) Valuation After Recent Mixed Share Price Performance
Novartis (SWX:NOVN) has drawn fresh attention after recent share price moves, with the stock showing mixed short term returns but a stronger result over the past 3 months and year. See our latest analysis for Novartis. Recent trading has been softer, with a 7 day share price return of 3.19% and a 30 day share price return of a 0.13% decline. However, the 90 day share price return of 14.54% and 1 year total shareholder return of 28.46% indicate that momentum has been building over a longer...